出品|达摩财经超60亿美元牵手辉瑞,三生制药、三生国健成为近期炙手可热的国产创新药公司。5月20日,三生制药(1530.HK)发布公告称,公司及附属公司三生国健(688336.SH)与辉瑞公司就PD-1/VEGF双特异性抗体SSGJ-707(下称“707项目”)达成合作协议。三生制药、三生国健将把707项目除中国内地外的全球开发、生产及商业化权益授权给辉瑞。根据协议,此次交易的首付款为12.5...
Source Link出品|达摩财经超60亿美元牵手辉瑞,三生制药、三生国健成为近期炙手可热的国产创新药公司。5月20日,三生制药(1530.HK)发布公告称,公司及附属公司三生国健(688336.SH)与辉瑞公司就PD-1/VEGF双特异性抗体SSGJ-707(下称“707项目”)达成合作协议。三生制药、三生国健将把707项目除中国内地外的全球开发、生产及商业化权益授权给辉瑞。根据协议,此次交易的首付款为12.5...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.